# US Anti VEGF Market > US Anti-VEGF Market Research Report By Product (Eylea, Lucentis, Beovu) and By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.3% - **2024:** $ 4,547.2 Million - **2025:** $ 4,742.73 Million - **2035:** $ 7,227.15 Million - **Key Players:** Regeneron Pharmaceuticals (US), Roche (CH), Novartis (CH), Bayer (DE), Pfizer (US), Amgen (US), Eli Lilly and Company (US), Santen Pharmaceutical (JP), Hikma Pharmaceuticals (GB) **Report ID:** MRFR/HC/50451-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-anti-vegf-market-52209 --- ## Market Summary ## **US Anti-VEGF Market Overview:** As per MRFR analysis, the US Anti-VEGF Market Size was estimated at 5.23 (USD Billion) in 2023. The US Anti-VEGF Market Industry is expected to grow from 5.8(USD Billion) in 2024 to 9 (USD Billion) by 2035. The US Anti-VEGF Market CAGR (growth rate) is expected to be around 4.075% during the forecast period (2025 - 2035). ### **Key US Anti-VEGF Market Trends Highlighted** The US Anti-VEGF Market is primarily driven by the increasing prevalence of retinal diseases, including diabetic retinopathy and age-related macular degeneration (AMD). As older individuals are more susceptible to these conditions, the ageing population makes a substantial contribution to this increase. In addition to the demographic transition, improvements in drug formulations and delivery methods are propelling patient outcomes and enhancing the efficacy of treatment. New therapies that target these pathways are being developed because of the increasing comprehension of vascular endothelial growth factor (VEGF) signaling, which is expanding the treatment options available to healthcare providers. The potential to combine Anti-VEGF therapy with other treatment modalities, such as corticosteroids or laser therapy, is a prominent opportunity to be explored in the US market. This method may result in enhanced patient outcomes and may be of interest to healthcare systems that are developing cost-effective solutions. In addition, there is a growing emphasis on personalized medicine, which has the potential to create novel patient management pathways by customizing anti-VEGF treatments to individual patient profiles. Trends in the US anti-VEGF market have recently indicated a transition towards a greater demand for biosimilars. With the expiration of patents for the most prominent anti-VEGF therapies, biosimilars are offering more affordable alternatives, which have the potential to decrease healthcare expenditures. New opportunities for improving treatment adherence and efficacy in the long term are emerging as technology is increasingly integrated into patient management. Source: Primary Research, Secondary Research, _Market Research Future_ Database, and Analyst Review ## **US Anti-VEGF Market Drivers** ### Increasing Prevalence of Age-Related Macular Degeneration (AMD) The increasing prevalence of Age-Related Macular Degeneration (AMD) is a significant driver for the US anti-VEGF market Industry. According to the National Eye Institute, it is expected that by 2050, the number of Americans affected by AMD may reach 3.7 million, which highlights a growing number of potential patients for anti-VEGF therapies. As the population ages, particularly with the Baby Boomer generation retiring, the demand for effective treatments for AMD is expected to surge. This demographic shift necessitates innovative anti-VEGF solutions, prompting investment from leading pharmaceutical companies like Regeneron Pharmaceuticals and Novartis, which have been pivotal in advancing treatment options through Research and Development initiatives. Their considerable market presence and continued focus on AMD-related therapies further solidify the forecasted growth within the US Anti-VEGF Market. ### Advancements in Drug Formulations and Delivery Systems Innovations in drug formulations and delivery systems for anti-VEGF treatments are driving growth in the US anti-VEGF market Industry. Recent developments, such as extended-release formulations and devices allowing for more convenient administration of treatments, enhance patient compliance and treatment efficacy. For instance, companies like Regeneron are exploring new delivery methods that reduce the frequency of injections. A study published in the Journal of Ocular Pharmacology and Therapeutics highlights that improved delivery systems can enhance patient adherence by as much as 30%, ultimately expanding the market by reaching previously underserved patient populations. ### Rising Awareness and Early Detection of Ocular Diseases Rising awareness and early detection of ocular diseases have significantly influenced the US anti-VEGF market Industry. Campaigns from the American Academy of Ophthalmology have been instrumental in promoting regular eye exams, increasing the number of diagnosed cases of diseases like diabetic retinopathy and AMD. This is crucial, as the Centers for Disease Control and Prevention indicate that diabetic eye disease affects 7.7 million Americans, signifying a growing market for treatment options. Early detection coupled with the availability of anti-VEGF therapies provides a strong rationale for patients to seek out these treatments, ultimately fostering market growth. ### Supportive Regulatory Frameworks for Anti-VEGF Therapies Supportive regulatory frameworks play a vital role in driving the US anti-VEGF market Industry. The U.S. Food and Drug Administration's streamlined approval processes for new anti-VEGF therapies and indications encourage innovation and ensure rapid availability of effective treatments to patients. In recent years, the FDA has been proactive in expediting review timelines for drug applications, particularly for groundbreaking treatments for serious conditions such as AMD and diabetic retinopathy. This supportive regulatory landscape not only fosters a competitive market but also incentivizes companies to invest further in Research and Development, thereby accelerating the introduction of advanced anti-VEGF options to meet the needs of a growing patient population. ## **US Anti-VEGF Market Segment Insights:** ### **Anti-VEGF Market Product Insights  ** The US Anti-VEGF Market, characterized by its crucial role in addressing retinal diseases such as Age-related Macular Degeneration and Diabetic Retinopathy, showcases a robust product segmentation. Eylea, Lucentis, and Beovu represent significant components within this sector, each contributing uniquely to the treatment landscape. Eylea has gained notable traction owing to its extended dosing interval, thereby enhancing patient compliance and reducing the frequency of injections for those suffering from visual impairments resulting from retinal vascular diseases. Lucentis, as one of the pioneering anti-VEGF therapies, holds a formidable presence in the market, credited with demonstrating substantial efficacy in numerous clinical studies over the years. Its established use in clinical practice supports a loyal adoption among healthcare providers. On the other hand, Beovu, while being relatively newer to the market, has captured attention due to its potential for extended intervals between doses, positioning it as a competitive option. This diversity among the products allows for tailored treatment plans, accommodating various patient needs and preferences, which is critical in the US healthcare landscape. The US Anti-VEGF Market has seen a progressive shift towards these therapeutics, driven by factors such as rising incidences of retinal diseases, an aging population, and increased awareness among patients regarding treatment options. However, the market also faces challenges, including high treatment costs and the potential for adverse effects associated with long-term use. Nevertheless, opportunities abound in this market segment, particularly as ongoing Research and Development efforts yield innovations aimed at improving the efficacy and safety profiles of these therapies. Overall, the product segmentation within the US Anti-VEGF Market remains vital in addressing the growing burden of vision loss and continues to evolve in response to patient and clinician demands. Source: Primary Research, Secondary Research, _Market Research Future_ Database, and Analyst Review ### **Anti-VEGF Market Disease Insights  ** The US Anti-VEGF Market focuses significantly on the Disease segment, addressing critical conditions such as Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, and Age-Related Macular Degeneration. These conditions are prevalent in the aging population, which is expected to rise, thereby increasing the demand for anti-VEGF therapies in the US. Macular Edema leads to vision impairment and, if untreated, can result in irreversible damage, highlighting its importance in the market landscape. Diabetic Retinopathy, a leading cause of vision loss among people with diabetes, requires effective management through Anti-VEGF treatments, showcasing its significance in both public health and market growth. Retinal Vein Occlusion is another condition that has garnered attention due to its high incidence rate among older adults. Meanwhile, Age-Related Macular Degeneration is a leading cause of blindness in older adults, emphasizing its dominating position within the market due to its vast patient population. The challenges in these segments, such as the need for ongoing research and development, coupled with opportunities arising from technological advancements in treatment, shape the trajectory for growth within the US Anti-VEGF Market. Strategies focused on patient accessibility and education will continue to drive demand for Anti-VEGF therapies addressing these prevalent diseases. ### **US Anti-VEGF Market Key Players and Competitive Insights:** The competitive landscape of the US Anti-VEGF Market is characterized by a dynamic interplay of key players, innovative product offerings, and evolving treatment paradigms that reflect changing patient needs. The market is driven by the increasing prevalence of ophthalmic diseases such as age-related macular degeneration and diabetic retinopathy, leading to a growing demand for anti-VEGF therapies. As multiple companies strive to capture market share, their strategies encompass research and development, strategic partnerships, and extensive clinical trials. Firms are also exploring biosimilars as a means to improve accessibility and affordability, thereby attracting a broader patient base. The competitive insights manifest in the continuous refinement of existing products and the introduction of novel therapies aimed at enhancing efficacy and reducing treatment burden for patients. In the US Anti-VEGF Market, Roche stands out due to its strong portfolio and a reputation for scientific innovation. The company has established a prominent market presence with its flagship products that have set the benchmark for efficacy in treating various retinal diseases. Roche’s strength lies in its robust research and development capabilities, which pave the way for continuous product improvement and innovation. The firm has secured a significant market share through strategic alliances and partnerships with healthcare providers, enhancing its distribution network. Its commitment to addressing unmet clinical needs has bolstered its reputation among patients and healthcare professionals alike, allowing Roche to maintain its competitive edge in a rapidly evolving landscape. Amgen also plays a vital role in the US Anti-VEGF Market, offering a range of effective treatment options that address various ophthalmic conditions. The company's key products have been well-received, and its established presence in both the pharmaceutical and biotechnology sectors enhances its credibility. Amgen's strengths lie in its advanced research initiatives and dedication to developing cutting-edge therapies designed to improve patient outcomes. Recent mergers and acquisitions have further solidified Amgen's position in the market, enabling it to expand its capabilities and product offerings. The strategic alignment with other firms has allowed Amgen to leverage synergies that boost operational efficiency and foster innovation. In navigating the complexities of the market, Amgen continues to target specific patient segments, ensuring that its anti-VEGF therapies meet the evolving needs of US healthcare providers and patients alike. ### **Key Companies in the US Anti-VEGF Market Include:** ## **US Anti-VEGF Market Industry Developments** In recent months, the US Anti-VEGF Market has witnessed notable developments, particularly as companies like Regeneron Pharmaceuticals and Bayer continue to expand their product offerings and enhance their market presence. Regeneron’s Eylea remains a leading treatment for retinal diseases, and the company is actively pursuing label expansions to bolster its usage. Moreover, in September 2023, Horizon Therapeutics announced a strategic collaboration with AbbVie to develop new treatments in the space, aiming to leverage AbbVie's strong portfolio in eye care. Notably, Amgen's acquisition of WeWork's subsidiary in August 2023 indicates a focus on integrating new technologies for patient engagement and treatment adherence. Growth in the US Anti-VEGF Market is driven by rising incidences of age-related macular degeneration and diabetic retinopathy, prompting increased investments in Research and Development from key players, including Novartis and Bristol Myers Squibb. With market dynamics shifting, regulatory approvals for innovative therapies are expected to influence the competitive landscape in the future. Over the past two years, significant advancements have included the FDA approval of new anti-VEGF agents, enhancing treatment options for patients across the US. ## **Anti-Vegf Market Segmentation Insights** - ### **Anti-VEGF Market Product Outlook** - Eylea - Lucentis - Beovu - ### **Anti-VEGF Market Disease Outlook** - Macular Edema - Diabetic Retinopathy - Retinal Vein Occlusion - Age-Related Macular Degeneration ** ** ## Market Drivers ### Growing Awareness of Vision Health The anti vegf market is benefiting from the growing awareness of vision health among the general population. Educational campaigns and initiatives aimed at promoting eye health are encouraging individuals to seek regular eye examinations and treatment for retinal diseases. This heightened awareness is likely to lead to earlier diagnosis and treatment of conditions such as diabetic retinopathy and AMD, which are commonly treated with anti-VEGF therapies. As more patients become informed about the importance of maintaining vision health, the demand for anti-VEGF treatments is expected to rise, further propelling the growth of the anti vegf market. ### Rising Healthcare Expenditure on Eye Care The anti vegf market is influenced by the rising healthcare expenditure on eye care in the United States. With an increasing focus on preventive care and early intervention, healthcare spending on ophthalmic treatments is expected to rise. According to recent data, the U.S. healthcare expenditure on eye care is projected to reach $40 billion by 2025. This increase in funding is likely to facilitate the development and accessibility of anti-VEGF therapies, making them more available to patients in need. As healthcare providers prioritize eye health, the anti vegf market stands to gain from enhanced investment in research and development, ultimately leading to more effective treatment options. ### Increased Research and Development Investments The anti vegf market is experiencing a surge in research and development investments aimed at discovering new therapeutic options. Pharmaceutical companies are increasingly allocating resources to develop next-generation anti-VEGF agents that may offer improved efficacy and safety profiles. This trend is supported by the growing recognition of the need for innovative treatments to address the limitations of existing therapies. As R&D investments continue to rise, the anti vegf market is likely to witness the introduction of novel therapies that could reshape treatment paradigms and enhance patient outcomes in the management of retinal diseases. ### Technological Innovations in Ophthalmic Treatments Technological advancements in ophthalmic treatments are playing a crucial role in the anti vegf market. Innovations such as sustained-release drug delivery systems and minimally invasive surgical techniques are enhancing the efficacy and safety of anti-VEGF therapies. For instance, recent developments in implantable devices that provide continuous drug release could potentially reduce the frequency of injections required for patients. This not only improves patient compliance but also reduces the overall treatment burden. The anti vegf market is likely to benefit from these advancements, as they may lead to improved therapeutic outcomes and increased adoption of anti-VEGF therapies among healthcare providers. ### Increasing Prevalence of Age-Related Macular Degeneration The anti vegf market is experiencing growth due to the rising prevalence of age-related macular degeneration (AMD) in the United States. As the population ages, the incidence of AMD is projected to increase significantly, with estimates suggesting that by 2030, approximately 3 million Americans will be affected. This condition leads to vision loss and necessitates effective treatment options, driving demand for anti-VEGF therapies. The anti vegf market is responding to this need by developing innovative therapies that target the underlying mechanisms of AMD, thereby improving patient outcomes. Furthermore, the increasing awareness of AMD and its impact on quality of life is likely to encourage more individuals to seek treatment, further propelling the growth of the anti vegf market. ## Future Outlook The [Anti VEGF Market](https://www.marketresearchfuture.com/reports/anti-vegf-market-21963) is projected to grow at a 4.3% CAGR from 2025 to 2035, driven by increasing prevalence of retinal diseases and advancements in treatment options. **New opportunities:** - Development of combination therapies to enhance efficacy and patient compliance. - Expansion of telehealth services for remote patient monitoring and consultations. - Investment in AI-driven diagnostics to streamline treatment pathways and improve outcomes. By 2035, the anti-VEGF market is expected to solidify its position as a leader in ocular therapeutics. ## Segment Insights ### By Product: Eylea (Largest) vs. Beovu (Fastest-Growing) In the US anti vegf market, the product segment is primarily dominated by Eylea, which holds a significant share due to its established presence and efficacy in treating retinal diseases. Lucentis follows but has seen a decline in preference as new therapies emerge. Beovu, introduced more recently, is gaining traction among healthcare providers, contributing to a shifting landscape in the treatment options available to patients. Growth trends in this segment highlight a clear movement towards newer therapies like Beovu, which offer enhanced dosing schedules and improved patient outcomes. The increasing incidence of retinal diseases, coupled with a growing aging population, drives demand for innovative treatments. Furthermore, ongoing research and development efforts are expected to bolster the presence of these products in the market, with a focus on long-term efficacy and patient convenience. Eylea (Dominant) vs. Beovu (Emerging) Eylea stands as the dominant force in the product segment, known for its robust clinical efficacy and comprehensive treatment protocols. Its market position is reinforced by extensive clinical data supporting its use for various retinal diseases, appealing to both healthcare providers and patients. Conversely, Beovu is recognized as the emerging player, capturing interest with its unique dosing regimen and potentially fewer injections required over time. This emerging product is well-positioned to attract a growing segment of patients looking for convenience and effectiveness. As healthcare professionals increasingly adopt Beovu in their treatment paradigms, the competition between these two products could redefine therapeutic choices in the US anti vegf market. ### By Disease: Age-Related Macular Degeneration (Largest) vs. Diabetic Retinopathy (Fastest-Growing) In the US anti vegf market, Age-Related Macular Degeneration holds a large share, making it a significant contributor to the overall market dynamics. Its prevalence among the aging population positions it as a dominant segment. In contrast, Diabetic Retinopathy, fueled by the increasing incidence of diabetes, has emerged as a fast-growing segment, capturing attention due to its rising patient demographic. The growth trends in this market segment are driven by advancements in treatment options and heightened awareness of eye health. The rising prevalence of conditions like Diabetic Retinopathy showcases the importance of targeting these diseases effectively. Furthermore, collaborations among healthcare providers and pharmaceutical companies aim to enhance accessibility and improve treatment outcomes, contributing to the expanding market landscape for anti-VEGF therapies. Macular Edema (Dominant) vs. Retinal Vein Occlusion (Emerging) Macular Edema is recognized as a dominant segment in the US anti vegf market, largely due to its association with common conditions such as Diabetic Retinopathy and Age-Related Macular Degeneration. Its consistent treatment demand stems from the need to manage vision impairment effectively. In contrast, Retinal Vein Occlusion, while currently considered an emerging segment, shows potential for significant growth. This condition's complex nature and varying prevalence call for targeted treatment strategies, which, along with increased awareness and diagnostic advances, position it as a territory ripe for future development within the market. ## Competitive Benchmarking The anti-VEGF market is characterized by intense competition and rapid innovation, driven by the increasing prevalence of retinal diseases and the growing demand for effective therapies. Key players such as Regeneron Pharmaceuticals (US), Roche (CH), and Novartis (CH) are at the forefront, leveraging their extensive research capabilities and established market presence. Regeneron Pharmaceuticals (US) focuses on continuous innovation, particularly with its flagship product, Eylea, which has seen significant uptake due to its efficacy in treating age-related macular degeneration (AMD). Roche (CH) emphasizes strategic partnerships and collaborations to enhance its product pipeline, while Novartis (CH) is investing heavily in digital transformation to streamline operations and improve patient access to therapies. Collectively, these strategies contribute to a competitive landscape that is both dynamic and multifaceted. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that hold substantial influence. This competitive environment fosters innovation and encourages companies to differentiate their offerings through advanced technologies and improved patient outcomes. In October 2025, Regeneron Pharmaceuticals (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to Eylea. This move is significant as it aligns with the growing trend of digital health solutions, potentially increasing patient adherence and expanding market reach. By integrating telehealth services, Regeneron aims to address barriers to treatment, thereby enhancing its competitive positioning in the anti-VEGF market. In September 2025, Roche (CH) launched a new clinical trial for its investigational anti-VEGF therapy, which targets a broader range of retinal diseases. This initiative underscores Roche's commitment to innovation and its strategy to diversify its product offerings. The trial's outcomes could potentially reshape treatment paradigms, positioning Roche as a leader in the evolving landscape of retinal therapies. In August 2025, Novartis (CH) unveiled a new digital platform aimed at improving patient engagement and education regarding its anti-VEGF treatments. This platform is designed to provide personalized information and support, reflecting Novartis's focus on enhancing the patient experience. By leveraging technology, Novartis seeks to strengthen its market presence and foster loyalty among healthcare providers and patients alike. As of November 2025, current trends in the anti-VEGF market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies compete, emphasizing the importance of delivering superior patient outcomes and enhancing operational efficiencies. ## Recent News & Developments In recent months, the US Anti-VEGF Market has witnessed notable developments, particularly as companies like Regeneron Pharmaceuticals and Bayer continue to expand their product offerings and enhance their market presence. Regeneron’s Eylea remains a leading treatment for retinal diseases, and the company is actively pursuing label expansions to bolster its usage. Moreover, in September 2023, Horizon Therapeutics announced a strategic collaboration with AbbVie to develop new treatments in the space, aiming to leverage AbbVie's strong portfolio in eye care. Notably, Amgen's acquisition of WeWork's subsidiary in August 2023 indicates a focus on integrating new technologies for patient engagement and treatment adherence. Growth in the US Anti-VEGF Market is driven by rising incidences of age-related macular degeneration and diabetic retinopathy, prompting increased investments in Research and Development from key players, including Novartis and Bristol Myers Squibb. With market dynamics shifting, regulatory approvals for innovative therapies are expected to influence the competitive landscape in the future. Over the past two years, significant advancements have included the FDA approval of new anti-VEGF agents, enhancing treatment options for patients across the US. ## Report Scope | MARKET SIZE 2024 | 4547.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 4742.73(USD Million) | | MARKET SIZE 2035 | 7227.15(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.3% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Roche (CH), Novartis (CH), Bayer (DE), Pfizer (US), Amgen (US), Eli Lilly and Company (US), Santen Pharmaceutical (JP), Hikma Pharmaceuticals (GB) | | Segments Covered | Product, Disease | | Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance growth potential in the anti vegf market. | | Key Market Dynamics | Intensifying competition and regulatory scrutiny drive innovation in the anti VEGF market, reshaping treatment paradigms. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall valuation of the US anti VEGF market in 2024?** A: The overall market valuation was $4547.2 Million in 2024. **Q: What is the projected market valuation for the US anti VEGF market by 2035?** A: The projected valuation for 2035 is $7227.15 Million. **Q: What is the expected CAGR for the US anti VEGF market during the forecast period 2025 - 2035?** A: The expected CAGR for the US anti VEGF market during the forecast period 2025 - 2035 is 4.3%. **Q: Which companies are considered key players in the US anti VEGF market?** A: Key players in the market include Regeneron Pharmaceuticals, Roche, Novartis, Bayer, Pfizer, Amgen, Eli Lilly and Company, Santen Pharmaceutical, and Hikma Pharmaceuticals. **Q: What were the sales figures for Eylea in 2024?** A: Sales figures for Eylea ranged from $2000.0 Million to $3200.0 Million in 2024. **Q: How did Lucentis perform in terms of sales in 2024?** A: Lucentis sales figures were between $1500.0 Million and $2200.0 Million in 2024. **Q: What was the market performance of Beovu in 2024?** A: Beovu generated sales between $1047.2 Million and $1827.15 Million in 2024. **Q: Which disease segments are included in the US anti VEGF market analysis?** A: The disease segments include Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, and Age-Related Macular Degeneration. **Q: What were the sales figures for Age-Related Macular Degeneration in 2024?** A: Sales figures for Age-Related Macular Degeneration ranged from $1547.2 Million to $2437.15 Million in 2024. **Q: What is the projected growth for Diabetic Retinopathy in the US anti VEGF market by 2035?** A: The market for Diabetic Retinopathy is expected to grow from $1200.0 Million to $1900.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-anti-vegf-market-52209*